产品
编 号：F006880
分子式：C21H19N5O4S
分子量：437.47
分子式：C21H19N5O4S
分子量：437.47
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1016543-77-3
产品详情
生物活性：
S516 (Compound 22) is an active metabolite of CKD-516 and a potent tubulin polymerization inhibitor with an IC50 of 4.29 μM. S516 has marked antitumor activity.
体内研究：
S516 (Compound 22; 5-10 mg/kg; intraperitoneal injection; mice) treatment has promising antitumor activity (inhibition ratio (IR)> 63%) in human LX-1 lung cancer and CX-1 colon cancer mouse xenografts.Animal Model:Mice bearing 3LL lung cancer
Dosage:5 mg/kg, 10 mg/kg
Administration:Intraperitoneal injection
Result:Had promising antitumor activity (inhibition ratio (IR)> 63%).
体外研究：
S516 has potent cytotoxicity with IC50s of 4.8 nM, 42.8 nM and 24.9 nM for HL-60, HCT116 and HCT15 cells, respectively.S516 (Compound 22; 30 nM; 16 hours; HL60 cells) treatmemt causes significant arrest of cells at the G2/M phase, resulting in apoptosis with concomitant loss of G0/G1 phase.
S516 (Compound 22) is an active metabolite of CKD-516 and a potent tubulin polymerization inhibitor with an IC50 of 4.29 μM. S516 has marked antitumor activity.
体内研究：
S516 (Compound 22; 5-10 mg/kg; intraperitoneal injection; mice) treatment has promising antitumor activity (inhibition ratio (IR)> 63%) in human LX-1 lung cancer and CX-1 colon cancer mouse xenografts.Animal Model:Mice bearing 3LL lung cancer
Dosage:5 mg/kg, 10 mg/kg
Administration:Intraperitoneal injection
Result:Had promising antitumor activity (inhibition ratio (IR)> 63%).
体外研究：
S516 has potent cytotoxicity with IC50s of 4.8 nM, 42.8 nM and 24.9 nM for HL-60, HCT116 and HCT15 cells, respectively.S516 (Compound 22; 30 nM; 16 hours; HL60 cells) treatmemt causes significant arrest of cells at the G2/M phase, resulting in apoptosis with concomitant loss of G0/G1 phase.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备